CERIBELL INC

Company Overview

Ceribell Inc. (CBLL) is a California-based medical device company in the Medical Devices / Medical Equipment space that sells a rapid EEG monitoring system (recorder/Clarity) and single-use headbands, with an increasingly subscription-based revenue model. In Q2 2025 the company reported $21.2M of revenue (driven by ~38–39% product growth and 41% subscription growth), more than 550 active accounts and use in over 200,000 patients, but remains unprofitable with an accumulated deficit and an operating loss as it scales. Management is investing heavily in R&D, clinical studies, and a larger commercial organization to broaden indications and expand internationally, while managing supply-chain dual sourcing and a modest term facility plus ~$177M in cash and marketable securities. The business is characterized by recurring headband and subscription economics, seasonal ICU-driven demand and quarter-to-quarter revenue variability.

Executive Compensation Practices

Compensation is likely to emphasize commercial and recurring-revenue KPIs (new account adds, active account growth, headband utilization, subscription ARR) and margin or gross-profit improvement as primary annual incentive drivers given the company’s shift toward subscription economics. As a growth-stage public medical device firm with continued operating losses and an IPO-funded balance sheet, the company will typically favor equity-heavy long-term incentives (options/RSUs and milestone-based grants) over large cash bonuses to conserve cash, with performance vesting tied to regulatory/clinical milestones, revenue/ARR thresholds, and commercialization achievements. R&D and regulatory priorities (broader indications, international approvals) make multi-year, milestone-linked awards common, and retention awards may be used to stabilize leadership through the transition to a larger public-company cost base and ongoing IP litigation. Public-company governance will also push more explicit pay-for-performance metrics and disclosure of peer benchmarking, bonus formulas, and any special litigation-related compensation.

Insider Trading Considerations

Insider trading patterns for Ceribell will be driven by IPO-related dynamics (large insider equity stakes and lock-up expirations), the cadence of binary regulatory/clinical updates, and quarterly seasonality in ICU volumes that create revenue volatility. Expect Section 16 reporting, common use of Rule 10b5-1 trading plans for predictable sales (tax/option-exercise needs), and careful blackout windows around earnings, clinical study readouts, reimbursement or regulatory filings, and material litigation events (the new patent infringement claim). Watch for insider sales tied to post-IPO diversification, secondary offerings or S-8 issuances for employee plans, and any unusual timing near supply-chain or cash-runway disclosures—such trades can materially impact short-term price action in this small-cap medical device name.